Jumet, November 8, 2021 – Graftys SA, a company specialized in the design and manufacture of bone graft substitutes for orthopedic surgery, announces its acquisition of Biologics4Life, a French company which is developing a new generation of injectable synthetic bone graft materials. To achieve its new development and commercial ambitions, Graftys raised $3M from Go Capital via its Ouest Venture 3 fund along with Noshaq and other European investors. This fundraising will be complemented with investment from Belgian, French and other European public subsidies.
Graftys is an innovative company headquartered in Belgium, with a subsidiary in France (Aix-en-Provence). The firm manufactures a range of first-in-class resorbable calcium phosphate cement in its ISO certified facilities.. Its innovative products are commercialized in more over 25 countries (including US and Brazil) with clearance from FDA, CDMAS, Anvisa and European notified body. Revenues in 2021 reached several million Euros.
Biologics 4 life is an early stage company committed to the design and development of advanced biomaterial technologies to treat bone metabolic disorders. Their focus has been on combination materials including active principles for treatment of osteoporotic fractures and bone metastases.
Graftys’ acquisition of Biologics4Life will build its expertise in bone graft and in advanced treatment for patients suffering from fracture or bone loss. The combination will strengthen cross-functional capabilities in R&D, manufacturing, regulatory affairs, and global commercialization.
Aurélien Valet & Sébastien Genesta, former Managing Directors at Biologics4Life, will assume executive roles in the management of Graftys, joined by their CFO, Xavier Ferry. Board of directors of Graftys SA will be partially renewed and reinforced.
« After three years of intensive product development work, we are pleased to join Graftys and its financial partners to greatly accelerate R&D, clinical work, and commercialization of our technology, » said Aurelien Vale and Sébastien GENESTA co-founders of Biologics4Life.
« The advanced product development, the excellent quality of academic and medical partnerships as well as the reputations of Biologics4Life’ founders in the bone substitute field have convinced GO CAPITAL to reinvest in Graftys and to complete the acquisition of Biologics4Life. The combined organization provides a very strong platform for future development. » said Bruno Guicheux, Investment Director at GO CAPITAL.
*About GO CAPITAL
GO CAPITAL, an independent management company, is a key player in seed capital and risk capital in the regions. Based in Brittany, Pays de la Loire, Normandy, Centre Val de Loire and Région Sud, GO CAPITAL helps finance responsible innovation across the regions. Its team is made up of investors with complementary sectoral experience, and has a solid track record in deep tech. With more than 130 investments to its credit, GO CAPITAL manages more than €200M and mainly finances technology leaders in the digital, healthcare and future industry (energy transition, maritime economy, agri-agro, etc.) sectors.
More info : https://www.gocapital.fr/
**About The Innovation Fund
Created in February 2015, Innovation Fund invests in innovative startups and companies active in the field of chemistry and life sciences. The fund has a capital of €35m, financed for more than 50% by major companies in the sector, bringing unique industrial support value to the investment projects. The remaining 50% is held by national and regional investment funds, universities, banks and individuals. To date, the Innovation Fund has already invested in 352 companies.
More info: http://www.innovationfund.eu
*** About Noshaq
Noshaq is an investment fund with a portfolio of 474 companies, including over 85 companies in the life sciences. Noshaq is the reference financial partner for the creation and development of SMEs in the Liège region. Over the years, Noshaq has developed a range of financing vehicles, which are suited to market needs and trends, as well as its strategy. Every service provided by Noshaq (capital – loans – leasing) is always designed according to the requirements and needs of the owner-investor. The aim is always to have a lever effect on the company’s development.
Rennes, 11 October 2021 – GO CAPITAL, the multi-regional investor in innovation capital, is pleased to announce that Mohamed Abdesslam has joined the team as associate investment director. This cooptation comes at a time of growth for the management company.
STRENGTHENING OF THE TEAM DEDICATED TO THE OV4 FUND
Mohamed Abdesslam’s arrival relates to the forthcoming launch of the OV4 fund. The purpose of this Professional Private Equity Fund (FPCI) is to speed up the emergence of technology companies whose growth objectives are based on a sustainable growth.
With a target size of €50M minimum, the OV4 fund will cement GO CAPITAL’s position as a leader in technology investment in France’s Grand-Ouest region. The first investments will be made before the end of 2021.
A RECOGNISED EXPERTISE IN PRIVATE-EQUITY
Mohamed’s recognised expertise in private equity and impact investing will help provide sustainable support to innovative companies both in terms of financing and strategy. His expertise thus fits GO CAPITAL’s aspiration to incorporate CSR and impact into the management of its portfolio.
Mohamed Abdesslam began his career in structured finance at BNP Paribas, before moving to Crédit Agricole CIB’s General Inspectorate. In this role, he conducted audit and strategic analysis missions within the group’s international subsidiaries. He then spent 10 years working with Citizen Capital, a pioneer impact investing fund in France, as business manager then investment director. He was involved in around 20 innovation capital operations. At the end of 2018, he joined MAIF Avenir as fund manager, providing support to noteworthy groups such as Ulule, Home Exchange, Lovys, Snips, Edflex, JeStocke, Rise Up and Certideal. Mohamed Abdesslam is a graduate of Ecole Centrale de Nantes, HEC Paris and Sciences Po Paris.
Lire le communiqué de presse complet
Rennes, le 11 octobre 2021 – GO CAPITAL, investisseur multirégional en capital innovation, annonce l’arrivée de Mohamed Abdesslam en qualité de directeur d’investissement associé. Cette cooptation intervient dans un contexte de croissance de la société de gestion.
RENFORCEMENT DE L’ÉQUIPE DÉDIÉE AU FONDS OV4
L’arrivée de Mohamed Abdesslam est liée au lancement prochain du fonds OV4. Ce Fonds Professionnel de Capital Investissement (FPCI) a pour vocation de financer et d’accompagner le développement de sociétés technologiques dont la stratégie de développement repose sur une croissance durable.
Avec une taille cible de 50 M€ minimum, le fonds OV4 confortera la position de GO CAPITAL en tant que leader de l’investissement technologique du Grand Ouest. Les premiers investissements seront réalisés avant la fin 2021.
UNE EXPERTISE RECONNUE EN CAPITAL-INVESTISSEMENT
Les compétences reconnues de Mohamed en capital-investissement et en impact investing contribueront à offrir un accompagnement durable des sociétés innovantes tant sur le plan du financement que de l’accompagnement stratégique. Son expertise concorde ainsi avec la volonté de GO CAPITAL d’intégrer la RSE et l’impact dans la gestion de son portefeuille.
Mohamed Abdesslam a débuté sa carrière en financements structurés chez BNP Paribas puis à l’Inspection Générale du Crédit Agricole CIB. A ce poste, il réalisait des missions d’audit et d’analyses stratégiques au sein des filiales internationales du groupe. Il s’est ensuite engagé pendant 10 ans aux côtés de Citizen Capital, fonds pionnier d’impact investing en France, en tant que chargé d’affaires puis directeur d’investissement. Il a participé à la réalisation d’une vingtaine d’opérations en capital-innovation. Fin 2018, il a rejoint MAIF Avenir comme gérant de fonds, accompagnant des références notables comme Ulule, Home Exchange, Lovys, Snips, Edflex, JeStocke, Rise Up et Certideal. Mohamed Abdesslam est diplômé de l’Ecole Centrale de Nantes, d’HEC Paris et de Sciences Po Paris.
Nantes, France, October 4, 2021 — InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), expands its leadership team with three appointments. Mark Pykett, who brings more than 20 years of experience in the biopharmaceutical industry, joins as Chairman of the Board; Beatrice Lejeune, industrial pharmacist that played a key role in receiving market authorization for five drugs, was named to the newly-created role of Chief Regulatory Officer and joins the Executive Committee; and Prof. Brian Popko, an expert in the fields of neurodegenerative and neuroinflammatory diseases, joins the Scientific Advisory Board.
“Our growing team will play critical roles in building our organization as we advance our lead clinical-stage candidate for rare neuromuscular diseases through clinical development in patients and bringing a promising preclinical candidate for Multiple Sclerosis toward the clinic,” said Philippe Guédat, President and CEO of InFlectis BioScience.
“InFlectis has a promising pipeline of small molecules to treat rare neuromuscular diseases that uniquely exploit the ISR pathway to potentially delay or halt disease progression,” said Dr. Pykett. “The pharmaceutical industry is increasing its investment in new therapies that target diseases of central and peripheral nervous system. InFlectis is at the forefront of this field with mid-stage clinical programs and an efficient and defined path to market for ALS and CMT, rare diseases that currently have very limited treatment options.”
Dr. Pykett is Chief Executive Officer of Myrtelle, Inc., a private biotechnology company. He has over 25 years of pharmaceutical industry executive management experience. Prior to Myrtelle, Dr. Pykett was Chief Scientific Officer at PTC Therapeutics, after the acquisition of Agilis Biotherapeutics for up to $945 million, plus royalties, in 2018. He was also CEO of Agilis Biotherapeutics, CEO of Navidea Pharmaceuticals, President and Chief Operating Officer of Alseres Pharmaceuticals, President of CyGenics and CEO of Cytomatrix. He has also been a board member of both public and private organizations, including the biotech companies Pharming Group and Exubrion Therapeutics and the not-for-profit organization HealthBuilders developing healthcare infrastructure in Rwanda. Dr. Pykett holds a BA from Amherst College, a VMD and PhD from the University of Pennsylvania, and an MBA from Northeastern University. He also completed post-doctoral work at the University of Pennsylvania and Harvard University.
Béatrice Lejeune most recently led regulatory affairs at Labo’Life, during which time five marketing authorizations were granted to the company. Her 17 years at Labo’Life, fostered an expertise in the full life cycle of drug development, from early discovery to commercialization. Ms. Lejeune graduated from the University of Louvain Pharmacy School in Belgium and worked as a research associate in pharmacogenomics at the University of Florida.
Prof. Brian Popko is the William Frederick Windle Chair of Neurology and the Scientific Director of the Division of Multiple Sclerosis and Neuroimmunology at Northwestern University’s Feinberg School of Medicine. He is a member of the Scientific Advisory Board for the Charcot Marie Tooth Association, and of the NIH Cellular and Molecular Biology of Glia Study section. Prof. Popko has over 30 years of experience in the academic field. He obtained his PhD from the University of Miami School of Medicine he conducted his postdoc at Caltech studying myelinating glial cells development. Prof. Popko has dedicated his academic career to the study of CNS disorders, focusing on the disruption and deterioration of the myelin sheath, a critical component of the nervous system that leads to neurological disorders once compromised.
PARIS, July 21, 2021 /PRNewswire/ — Coave Therapeutics (pronounced ‘cove’; formerly Horama), a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces a €21.2 million ($25.1 million) expansion of its Series B funding round, bringing the total raised to €33.1 million ($39 million). This financing was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne.
Coave Therapeutics will use the proceeds from this fundraising to support the execution of its corporate strategy, which is focused on:
Rodolphe Clerval, Coave Therapeutics CEO, said, “I am very pleased to have successfully completed this fundraising and welcome the new investors alongside our existing investors. Coave Therapeutics is at an exciting point in its development as we look to develop and generate value from our enhanced and selective ALIGATER gene delivery platform. We are confident that this technology will allow us to generate a pipeline of transformative gene therapy products for the treatment of rare ocular and CNS indications.”
Bruno Montanari, Partner at Seroba Life Sciences, commented, “The potential for Coave Therapeutics to push the boundaries of gene therapy through its next-generation AAV vector platform was what attracted us to lead this financing. We are confident that this platform, which enables both targeted delivery and enhanced gene transduction, will allow the Company to generate its own pipeline of novel therapies as well as improving the effectiveness of more advanced gene therapies for rare diseases being developed by potential partners.”
Bruno Montanari, a Partner at Seroba Life Sciences, and François Lontrade from Théa Open Innovation have joined the Coave Therapeutics Board of Directors.
About Coave Therapeutics
Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Coave Therapeutics’ next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.
The Company is advancing a pipeline of novel therapies targeting rare ocular and brain diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Coave Therapeutics, which is headquartered in Paris (France), is backed by leading international life science and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, Sham Innovation Santé/Turenne
For more information, please visit www.coavetx.com
About Seroba Life Sciences
Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech. The team has deep investment and industry experience enabling Seroba to help entrepreneurs realise their ambitions whilst creating value for investors. The firm has three funds under management and has built a portfolio of investee companies across multiple indications. Seroba partners with entrepreneurs to create and build businesses around extraordinary science.
Follow our story at www.seroba-lifesciences.com
About Théa and Théa Open Innovation
Théa is the leading independent eye care group in Europe, specialized in the research, development and commercialization of eye-care products.
Set up twenty-seven years ago, this family laboratory, based in Clermont-Ferrand, has continued to expand by opening more than 30 affiliates and offices in Europe, Russia, North Africa, North and South America. Its products are available in more than 70 countries.
Théa Open Innovation is a sister company of Laboratoires Théa; its mission is to set up partnerships with companies and universities to help bringing to the market the most innovative products in ophthalmology.
For more information visit: www.theaopeninnovation.com/
About eureKARE
eureKARE is a pioneering new company focused on financing and building next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology.
eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry.
eureKARE is headquartered in Luxembourg, with a presence in France & Belgium.
For more information visit: https://eurekare.eu/ and follow us on LinkedIn.
Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase of ischemic stroke and thrombotic diseases, today announces the completion of recruitment in GARDEN, its phase 2 clinical study on the use of glenzocimab, a novel humanized monoclonal antibody fragment, in patients with COVID-19-induced Acute Respiratory Distress Syndrome (ARDS).
GARDEN (NCT04659109) is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 2 trial evaluating the efficacy and the safety of 1000mg glenzocimab, administered daily over three consecutive days.
“Platelets are recognized for their inflammatory role and as immune effector cells in the lungs. There is a true need for new treatment in acute lung injury. Glenzocimab as antiplatelet therapy may offer a useful adjunctive strategy to fight virus-induced diseases. We are proud to have kicked off this study in France despite complex sanitary and administrative conditions and I seize the opportunity to thank all healthcare professionals for their commitment in clinical research despite terrible conditions during the pandemic’s spikes.” says Professor Julien POTTECHER, Global Coordinator for the GARDEN trial and Head of the Department of Anesthesia-Resuscitation & Peri-Operative Medicine at Hautepierre Hospital at Strasbourg University Hospitals in France.
“We are proud to have completed patient recruitment for phase 2 of the GARDEN trial using glenzocimab in SARS-Cov-2-related ARDS. This novel antithrombotic treatment may offer a response to an urgent unmet medical need in COVID-19-induced ARDS in that it limits uncontrolled inflammation and prevents complications without causing bleeding. Brazil and the Alemão Osvaldo Cruz Hospital in Sao Paulo particularly, have made a major contribution, despite difficult COVID-19 conditions. We thank all health professionals who dedicated themselves to the success of this study.” says Doctor Victor A. Hamamoto SATO, Brazilian coordinating investigator for the GARDEN trial, nephrology department, Alemão Oswaldo Cruz Hospital, Sao Paulo, Brazil.
The primary objective of GARDEN (Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome) is to evaluate the safety and efficacy of glenzocimab in preventing clinical progression of the disease when added to standard of care in COVID-19 patients presenting with ARDS.
Two countries, France and Brazil, have actively participated in including a total of 62 evaluable patients for the GARDEN trial. Preliminary data suggest that glenzocimab is safely tolerated in COVID-19 patients with ARDS, a finding confirmed by the Drug Safety Monitoring Board (DSMB) for this trial.
About therapeutic candidate glenzocimab (ACT017)
Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab). This therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of the antithrombotic efficacy of glenzocimab and the safety of its inhibition of GPVI has been established both ex vivo and in vivo. This target is involved in growth of the thrombus but not in physiological hemostasis, which thus limits the bleeding risk associated with its inhibition.
https://acticor-biotech.com/ourproduct/
About glenzocimab and Stroke
Glenzocimab is being currently assessed as an add-on to standard of care therapy for ischemic stroke. Acticor Biotech has recently announced the completion of patient enrolment in ACTIMIS (NCT03803007), a multinational, multicenter, randomized, double-blind, placebo-controlled, single-parallel, escalating dose phase 1b/2a safety and efficacy study of glenzocimab.
The primary objective of this trial, involving 160 patients randomized to either 1000mg glenzocimab or its matching placebo, is to assess the safety of glenzocimab as an add-on to thrombolysis alone or thrombolysis plus thrombectomy.
About Acticor Biotech
Acticor Biotech is a clinical stage biotechnology company, a spin-off of INSERM, dedicated to developing an innovative treatment for acute thrombotic diseases, including ischemic stroke. Acticor Biotech has been built on the expertise and research conducted by the co-founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Prof. Philippe Billiald at Paris-Sud University.
Acticor Biotech is a partner in the BOOSTER consortium, dedicated to the management of, and new treatments for, cerebrovascular accidents in emergency situations.
Acticor Biotech is backed by a syndicate of European and International investors: Karista, Go Capital, Newton Biocapital, CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici & Armesa Foundation.
For more information, go to: https://acticor-biotech.com/
Paris, France and Munich, Germany, July 5, 2021 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the successful first in human implantations of its Topaz transfemoral tricuspid heart valve replacement system (“Topaz”).
Heart valve diseases are among the most serious cardiac conditions affecting more than 12.7 million patients in Europe. In the last decade minimally invasive catheter-based solutions have been developed for other heart valve diseases, but none have been designed specifically for the tricuspid valve.
Tricuspid regurgitation is a frequent and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for more than 99 % of patients with tricuspid regurgitation. The prognosis for patients without surgical repair is poor, with 2.2 years median survival. As such, there is an urgent need for minimally invasive, lower risk solutions to improve outcomes for patients with no other viable treatment options.
Topaz is an innovative device designed specifically to help patients suffering from severe tricuspid regurgitation without the need for open heart surgery. The Topaz device is the result of a French and German collaboration, and is implanted in a minimally invasive procedure through the patient’s femoral vein. It is designed specifically to fit the tricuspid valve anatomy and thus support ease of positioning and functionality.
Today’s announcement marks the successful first two implantations of Topaz in patients, which were done on a compassionate use basis.
The first patient to benefit from this technology is a 70-year-old woman with heart failure due to severe tricuspid regurgitation. She was no longer responding to medical treatment and considered inoperable given her condition and operative risk. The successful implantation of the Topaz tricuspid heart valve replacement system took place at University Hospital Henri Mondor in Créteil, France, on 7 June 2021, and was performed by Prof. Emmanuel Teiger and Dr. Romain Gallet de-Saint-Aurin with implantation time of 16 minutes. The Topaz device achieved complete correction of the tricuspid regurgitation, and the patient was discharged from hospital after four days and is returning to normal activity levels. TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System
The second patient to benefit from this technology is an 86-year-old woman with torrential tricuspid regurgitation with a big coaptation gap between the leaflets of the tricuspid valve who also was not considered suitable for open heart surgery or a repair intervention. The successful implantation of the Topaz tricuspid heart valve replacement system took place at Laboratoire du Centre Cardiologique du Nord in Saint-Denis, Paris, France on 28 June 2021, and was performed by Dr. Mohammed Nejjari and Dr. Julien Dreyfus with implantation time of 12 minutes. Again, the Topaz device achieved complete correction of the tricuspid regurgitation, and the patient was discharged from hospital after four days and is returning to normal activity levels.
Both procedures were proctored by Prof. Dr. Hendrik Treede of the University Medical Centre in Mainz, Germany, and Prof. Dr. Ulrich Schäfer of Marien Hospital in Hamburg, Germany. Building upon the success of these procedures, TRiCares is preparing a clinical study in the coming months to validate the value of its Topaz tricuspid heart valve replacement system for these types of patients, who until now have had no satisfactory treatment option.
Prof. Teiger, Head of Cardiology at University Hospital Henri Mondor, commented, “I am pleased to have conducted this pioneering procedure with the Topaz tricuspid valve replacement system, through which we have achieved a successful life-saving outcome for a patient with no other viable treatment options.”
Dr. Nejjari, interventional cardiologist at Laboratoire du Centre Cardiologique du Nord, commented, “The procedure is easy, intuitive and well controlled through the entire procedure, and it is remarkable how fast the patient recovered after the Topaz implantation.”
Professor Dr. Treede, cardiac surgeon at the University Medical Centre in Mainz, who proctored both procedures, commented, “I am delighted to have overseen the successful first implantations of the Topaz tricuspid heart valve replacement system, which represents a significant advancement in the potential treatment options for patients with tricuspid regurgitation.”
Professor Dr. Schäfer, interventional cardiologist at Marien Hospital in Hamburg, who also proctored both procedures, commented, “These successful procedures demonstrate the ease of use and the controlled positioning of the Topaz tricuspid heart valve replacement system even in challenging patient anatomies.”
Helmut Straubinger, CEO of TRiCares, commented, “I am very pleased to announce the successful first implantations of our Topaz tricuspid heart valve replacement system. I am proud of our team for developing an innovative solution which has the potential to benefit critically ill patients suffering from tricuspid regurgitation. These first results give us confidence as we look forward to a clinical study of Topaz in the coming months.”
Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces the end of recruitment in ACTIMIS, its phase 1b/2a study with glenzocimab (ACT017), a novel humanized monoclonal antibody fragment for use in patients with acute ischemic stroke.
ACTIMIS (NCT03803007) is a multinational, multicenter, randomized, double-blind, placebo- controlled, single-parallel, escalating dose phase 1b/2a safety and efficacy study of glenzocimab used as an add-on to standard of care therapy for acute ischemic stroke.
“We are proud to have completed patient recruitment for phase 1b/2a of the ACTIMIS study in Acute Ischemic Stroke with glenzocimab. This is a novel first-in-class treatment in this indication, which inhibits GPVI without increasing the risk of bleeding, and thus a source of new perspectives in the field. The development of several other drug candidates has failed in recent years, mainly due to safety concerns that included excessive bleeding risks. We are particularly grateful to all the investigators who have coped with such fast-paced recruitment despite the current COVID-19 pandemic. We would also like to seize this opportunity to applaud all healthcare providers who have stepped up during the pandemic to serve their patients.” says Prof. Mikael Mazighi, M.D., Ph.D., Coordinating Investigator for ACTIMIS.
In September 2020, Acticor Biotech had announced that the Target Dose of 1000mg in the first 60 patients of the study had been reached and this was confirmed by the Drug Safety Monitoring Board (DSMB).
The primary objective of this additional 100-patient group randomized to either 1000mg glenzocimab or its matching placebo was to evaluate the safety of glenzocimab as an add-on to thrombolysis alone or thrombolysis plus thrombectomy.
Six countries (France, Spain, Belgium, Germany, Switzerland and Italy) have actively participated in including a total of 166 patients for the ACTIMIS trial. No safety issues have so far been detected by the Drug Safety Monitoring Board (DSMB) at any point during this study.
**
About glenzocimab (ACT017), the Therapeutic Candidate
Acticor is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab). This therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of the antithrombotic efficacy of glenzocimab and the safety of its inhibition of GPVI has been established both ex vivo and invivo. This target is involved in growth of the thrombus but not in physiological hemostasis, which thus limits the bleeding risk associated with its inhibition.
https://acticor-biotech.com/ourproduct
About glenzocimab and COVID-19
Glenzocimab is also being assessed as a treatment for Acute Respiratory Distress Syndrome in COVID-19-infected patients (SARS-Cov-2) to contain the contribution of platelets to uncontrolled lung inflammation and thus prevent downstream complications due to pro- thrombotic conditions without inducing bleeding.
The primary objective of GARDEN (NCT04659109) – Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome study is to evaluate the effect of glenzocimab in preventing the clinical progression of disease when added to standard of care in COVID-19 patients presenting with Acute Respiratory Distress Syndrome.
About Acticor Biotech
Acticor Biotech is a clinical stage biotechnology company, a spin-off of INSERM, dedicated to developing an innovative treatment for acute thrombotic diseases, including ischemic stroke. Acticor Biotech has been built on the expertise and research conducted by the co-founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Prof. Philippe Billiald at Paris-Sud University.
Acticor Biotech is a partner in the BOOSTER consortium, dedicated to the management of, and new treatments for, cerebrovascular accidents in emergency situations.
Acticor Biotech is backed by a syndicate of European and International investors: Karista, Go Capital, Newton Biocapital, CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici & Armesa Foundation.
For more information, go to: https://acticor-biotech.com/
Photo de groupe
Paris, May 11th, 2021 – DessIA, an artificial intelligence (AI) based system design software for engineers, announces that it has raised €5.5 million from Supernova Invest, btov Partners, Go Capital and BPI. The investment will be used to strengthen the R&D and Sales teams and to further penetrate the European market, especially France and Germany.
Founded in 2017 by Steven Masfaraud (CTO) and Pierre-Emmanuel Dumouchel (CEO), DessIA aims to revolutionize the engineering industry with its explainable artificial intelligence platform. Its number one priority: automating design tasks to reduce development time and improve profitability. Furthermore, the platform helps engineers to make the best choices by exploring the entire design space. For instance, DessIA’s cloud platform can help find the ideal battery architecture or the best wiring for a jet engine.
A disruptive technology in the system design software space
While the need for automation and decision support has doubled since the beginning of 2020, engineering design software has evolved very little. DessIA enables engineers to boost their productivity and creativity via AI. Its software adopts the set of design rules that engineers have and then describes the thought pattern of a certain workflow to form a so called “Engineering bot”. Similar to the world of highly successful Robotic Process Automation (RPA), the use of such Engineering bots reduces the time needed for certain process steps by several orders of magnitudes (minutes or hours instead of weeks or months) and is particularly valuable in projects with repetitive tasks and/or a high number of expected requirement adjustments. DessIA calls this REA (“Robotic Engineering Automation”). DessIA’s aspiration “is to provide engineers with virtual companions (bots) in order to help them make the right decision in a technical, normative and commercial environment that is becoming increasingly complex” explains Pierre-Emmanuel Dumouchel, CEO of DessIA.
Several large industrial OEMs trust DessIA
Initially, DessIA decided to focus its efforts on the development of pre-configured Engineering bots for its customers in the fields of power transmission, batteries and wiring. First successes allowed the company to move towards a platform strategy for the construction and provision of generic Engineering bots. In doing so, DessIA’s clients in the automotive, aerospace and railway sector can improve the profitability of their projects and to reduce development time.
In order to reach additional customers, DessIA has already entered into a strategic partnership with Safran Engineering Services and other consulting and implementation partners.
Funding to fuel growth in France and abroad
This funding will allow DessIA to strengthen its sales team, accelerate the development of its bot platform in a no-code spirit and continue the development of new families of bots. One important objective is to expand sales activities into other European markets with Germany as the first country on the list.
After 4 years of developing DessIA on their own, the two founders Pierre-Emmanuel Dumouchel and Steven Masfaraud are “delighted to open a new chapter of DessIA alongside three renowned investors!”